To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy. Background: RAS mutation has been reported to be associated with aggressive tumor biology. However, the effect of RAS mutation on survival and patterns of recurrence after resection of CLM remains unclear. Methods: Somatic mutations were analyzed using mass spectroscopy in 193 patients who underwent single-regimen modern chemotherapy before resection of CLM. The relationship between RAS mutation status and survival outcomes was investigated. Results: Detected somatic mutations included RAS (KRAS/NRAS) in 34 (18%), PIK3CA in 13 (7%), and BRAF in 2 (1%) patients. At a median follow-up of 33 months, 3-year overall survival (OS) rates were 81% in patients with wild-type versus 52.2% in patients with mutant RAS (P = 0.002); 3-year recurrence-free survival (RFS) rates were 33.5% with wild-type versus 13.5% with mutant RAS (P = 0.001). Liver and lung recurrences were observed in 89 and 83 patients, respectively. Patients with RAS mutation had a lower 3-year lung RFS rate (34.6% vs 59.3%, P < 0.001) but not a lower 3-year liver RFS rate (43.8% vs 50.2%, P = 0.181). In multivariate analyses, RAS mutation predicted worse OS [hazard ratio (HR) = 2.3, P = 0.002), overall RFS (HR = 1.9, P = 0.005), and lung RFS (HR = 2.0, P = 0.01), but not liver RFS (P = 0.181). Conclusions: RAS mutation predicts early lung recurrence and worse survival after curative resection of CLM. This information may be used to individualize systemic and local tumor-directed therapies and follow-up strategies.
becoming less relevant because of inconsistent predictive power and lack of reproducibility due to selection bias. 5 Preoperative systemic therapy has increasingly been used as part of a multidisciplinary approach for patients with CLM to test the biologic aggressiveness of the tumor and select optimal candidates for surgery. 6 Our group has reported that pathologic response [7] [8] [9] and radiologic response 10, 11 to preoperative chemotherapy are powerful predictors of long-term outcomes for patients with CLM. However, in patients with CLM, there is strong variability in clinical presentation, biologic aggressiveness, and patterns of treatment failure, and no biomarker predicts these phenotypic differences.
During the past decade, mutation status of RAS family genes (predominantly KRAS and NRAS) has been shown to correlate with the effectiveness of anti-EGFR agents against unresectable metastatic colorectal cancer, 12, 13 and a possible prognostic role of these somatic gene mutations after resection of CLM in an era predating the use of preoperative chemotherapy has been reported. 14 Our group has recently reported that metachronous CLM detected after modern chemotherapy for the primary colorectal tumor are associated with a higher incidence of somatic gene mutations and worse survival. 15 In addition, while recently reported studies have indicated a per-patient concordance of mutation type between primary tumor and metastases, a higher rate of mutation has been identified in patients with metastases at particular sites (eg, peritoneum, lung, and brain metastases), suggesting that tumors with mutations have a propensity to metastasize to the lungs and brain. [16] [17] [18] [19] On the basis of these clinical findings, we hypothesized that somatic mutation status predicts survival outcomes and types of recurrence after curative resection of CLM. In this study, we investigated the impact of RAS mutation status on survival and patterns of recurrence in patients who underwent curative resection of CLM after preoperative modern chemotherapy.
METHODS

Study Population
The institutional review board of the University of Texas MD Anderson Cancer Center approved this study protocol (PA11-0653). The prospectively maintained liver resections database of the Department of Surgical Oncology was queried to identify all patients who underwent liver resection for CLM during the period from November 1997 through October 2011. We studied patients undergoing curative hepatectomy without concomitant radiofrequency ablation. Patients with a history of previous treatment for metastatic disease (chemotherapy, radiofrequency ablation, or resection) were excluded.
All patients included in this study received preoperative oxaliplatin-or irinotecan-based chemotherapy including the anti-
Preoperative, Intraoperative, and Postoperative Management
Before operation, all patients underwent a medical history, physical examination, laboratory evaluation, and imaging studies, including helical computed tomography (CT) of the chest, abdomen, and pelvis with a triphasic liver protocol. In selected patients, fluorodeoxyglucose positron emission tomography was used to rule out extrahepatic disease and confirm the metastatic nature of atypical lesions. Only patients with hepatic and extrahepatic disease amenable to complete and safe resection were considered for hepatectomy. In patients with an anticipated insufficient future liver remnant, preoperative portal vein embolization was used to induce hypertrophy.
During laparotomy, intraoperative sonography of the liver was performed to confirm the location of known CLM and their relation to the portal pedicles or the hepatic veins and to rule out the presence of previously undetected CLM. Parenchymal transection was carried out under total or selective hepatic inflow occlusion using the Cavitron Ultrasonic Surgical Aspirator (Valleylab, Boulder, CO) and salinelinked cautery (dissecting sealer DS 3.0, Tissuelink Medical, Inc, Dover, NH) as reported previously. 20 All specimens were subjected to histologic evaluation to confirm the diagnosis of metastatic colorectal cancer and determine the width of the tumor-free surgical margin. The degree of pathologic response of CLM to preoperative chemotherapy was defined according to the percentage of the CLM tumor surface area composed of viable tumor cells: major pathologic response was defined as less than 50% viable cells and minor pathologic response as 50% or more viable cells. 7 After surgery, chemotherapy was usually reintroduced to complete a total of 12 cycles including both preoperative and postoperative chemotherapy. Patients were reassessed every 4 months after completion of the second stage of liver resection. Radiological evidence or positive biopsy was required to confirm recurrence, and time and site of relapse were systematically recorded. Further treatment was decided according to the findings at reassessment.
DNA Extraction and Somatic Gene Mutation Profiling
Hematoxylin-eosin-stained slides from all CLM were reviewed by a gastrointestinal pathologist (D.M.M.). Tumor viability in the CLM specimens was checked to exclude specimens with tumor viability less than 5%. Areas with maximum amount of available tumor were selected for macrodissection. Tumor tissue was scraped from the glass slides under direct visualization or under a dissecting microscope, and DNA was extracted from tumor tissue using a QIAmp DNA Mini Kit (Qiagen, Valencia, CA).
Somatic gene mutations were assessed using mass spectrometry. DNA extracted from formalin-fixed, paraffin-embedded resected CLM was quantified and analyzed with Sequenom MassARRAY technology (Sequenom, Inc, San Diego, CA). 21 Sequenom's Mas-sARRAY system utilizes polymerase chain reaction amplification and single-base primer extension for mutation detection. [22] [23] [24] The MassARRAY system offers a highly effective method for profiling hundreds of somatic mutations in parallel. A high-throughput analysis of 159-point mutations in 33 genes commonly involved in solid tumors was performed in MD Anderson's Characterized Cell Line Core Facility. The genes tested for this study were AKT1, AKT2, AKT3, ALK, BRAF, CDK4, CTNNB1, DEAR1, EGFR, ERA, FRAP, GNAS, HIF1A, IDH1, IDH2, IGFR1R, JAK2, KIT, KRAS, MEK1, MET, NRAS, PDGFRA, PDPK1, PHLPP2, PIK3CA, PIK3R1, PRKAG1, PRKAG2, RET, RICTOR, STK11, and TNK2.
Statistical Analysis
Qualitative variables were expressed as frequencies. Patients were stratified according to KRAS or NRAS mutation status into 2 groups: mutant RAS and wild-type RAS. Clinicopathological features were compared between these 2 groups using χ 2 or Fisher exact tests, as appropriate. Overall survival (OS), overall recurrence-free survival (RFS), lung RFS, and liver RFS were calculated using the Kaplan-Meier method from the date of liver resection to the date of death, first recurrence at any site, lung recurrence, or liver recurrence, respectively. Patients without an event during the follow-up period were censored at the date of last follow-up. These survival outcomes were compared using the log-rank test.
To identify factors associated with OS and RFS in the entire study cohort, we evaluated the following clinicopathologic variables in a univariate analysis: disease-free interval after the primary tumor diagnosis (<12 months vs ≥12 months), primary tumor location (rectum vs colon), regional lymph node status of the primary tumor (positive vs negative), RAS mutation status (mutant vs wild-type), number of cycles of preoperative chemotherapy for CLM (>6 vs ≤6), pathologic response to preoperative chemotherapy (major vs minor), number of CLM in the pathologic specimen (multiple vs solitary), diameter of the largest of the CLM in the pathologic specimen (>5 vs ≤5 cm), and major postoperative complications were defined as complications of grade 3 or higher (necessitating a surgical, endoscopic, or radiological procedure) in the Dindo classification, 25 and liver resection margin status on microscopic analysis (positive vs negative).
All variables associated with OS, overall RFS, lung RFS, and liver RFS with P < 0.1 in the univariate proportional hazards models were entered into a Cox multivariate regression model with backward elimination. P < 0.05 was considered statistically significant. Statistical analyses were performed using the software IBM SPSS Statistics, version 19 (IBM, Armonk, NY).
RESULTS
Among 1406 consecutive patients treated for CLM at MD Anderson during the study period, 621 were excluded because of concomitant radiofrequency ablation or nonreceipt of preoperative chemotherapy. An additional 497 patients were excluded because they received multiple lines of preoperative chemotherapy, did not receive bevacizumab, received anti-EGFR agents before or after liver resection, had less than 5% viable tumor cells in the specimen, died within 90 days after surgery, or underwent a noncurative hepatectomy. Among the 288 patients eligible for the genetic testing, 95 patients were excluded because they did not have available paraffin blocks or had insufficient DNA for genetic analysis. The remaining 193 patients were studied in detail ( Fig. 1 ).
Somatic Gene Mutation Status
Of the 193 patients included in the study, 43 (22.3%) had 1 or more somatic mutations in tested genes. Thirty-four patients (17.6%) had RAS mutations (27 KRAS and 7 NRAS), 13 patients (6.7%) had PIK3CA mutations, 2 patients (1%) had BRAF mutations, and 2 patients (1%) had rare mutations-one had a CTNNB1 mutation, and the other had an AKT1 mutation ( Fig. 2 ). Among the 34 patients with RAS mutations, 29 (85%) exhibited a mutation at codon 12 (nucleotide changes: G→A in 17 patients, G→T in 8 patients, and G→C in 4 patients), 3 (9%) exhibited a mutation at codon 61 (A→G in 1 patient, A→C in 1 patient, and C→G in 1 patient), and 2 (6%) exhibited a mutation at codon 13 (G→A in both of them). Among the
Patient Characteristics by RAS Mutation Status
Clinicopathologic characteristics by RAS mutation status are shown in Table 1 . Patients with RAS mutation had a lower rate of major pathologic response (<50% viable tumor cells) than patients with wild-type RAS (38.2% vs 58.5%; P = 0.037). The remaining characteristics did not differ significantly between patients with mutant and wild-type RAS. disease recurrence, and 88 were alive with no evidence of disease at last follow-up. For the entire cohort, 3-and 5-year RFS rates were 29.9% and 26.9%, respectively, and 3-and 5-year OS rates were 76.4% and 61.8%, respectively. Patients with mutant RAS had worse long-term outcomes than those with wild-type RAS (3-year RFS: 13.5% vs 33.5%, P = 0.001; 3-year OS: 52.2% vs 81%, P = 0.002) ( Fig. 3) .
Long-term Survival and Predictors of Outcomes
In multivariate analysis, independent risk factors of worse RFS were RAS mutation [hazard ratio (HR) = 1.9; 95% CI: 1.2-3.0; P = 0.005] and minor pathologic response to preoperative chemotherapy (HR = 2.0; 95% CI: 1.4-3.0; P < 0.001) ( Table 2 ). Independent risk factors of worse OS also were RAS mutation (HR = 2.3; 95% CI: 1.1-4.5; P = 0.002) and minor pathologic response (HR = 2.1; 95% CI: 1.1-4.0; P = 0.022) ( Table 3 ).
Patterns of Recurrence and Predictors of Recurrence Pattern
Of the 126 patients who had tumor recurrence during the follow-up period, 83 patients had a lung recurrence and 89 patients had a liver recurrence. Patients with mutant RAS had worse 3-year lung RFS than those with wild-type RAS (34.6% vs 59.3%, P < 0.001) ( Fig. 4A , Table 4 ). In contrast, 3-year liver RFS was not influenced by RAS mutation (43.8% for mutant RAS vs 50.2% for wild-type RAS, P = 0.181) ( Fig. 4B , Table 4 ). At the last follow-up, lung recurrence was observed in 64.7% of patients with RAS mutation (22 of 34) versus 38.3% of patients with wild-type RAS (61 of 159) (P = 0.005). The incidence of liver recurrence did not correlate significantly with RAS mutation status (44.7% of patients with RAS mutation vs 52.9% of those with wild-type RAS; P = 0.379).
Multivariate analysis indicated that RAS mutation (HR = 2.0; 95% CI: 1.1-3.4; P = 0.01) and minor pathologic response (HR = 1.9; 95% CI: 1.1-3.0; P = 0.009) were independent predictors of lung RFS, whereas minor pathologic response was the only independent predictor of liver RFS (HR = 2.2; 95% CI: 1.4-3.5; P = 0.001) ( Tables 4 and 5 ).
DISCUSSION
In this study, we analyzed the prognostic impact of RAS mutation status in 193 patients who underwent curative resection of CLM after single-regimen modern systemic therapy. Consistent with previous oncogene profiling studies for primary colorectal cancers, RAS, BRAF, and PIK3CA were identified as the most common pointmutated genes in CLM. 23, 26 Our analysis indicates that RAS mutation status is an independent predictor of OS, overall RFS, and lung RFS, but not liver RFS after resection of CLM. The current study also confirms our previous study indicating the preeminence of response to chemotherapy as a dynamic biological predictor of outcome superior to traditional clinical pathological predictors such as number of liver metastases, size of liver metastases, lymph node status of primary tumor, or surgical margins. 7, 27 Over the past to curative resection. This suggests that among patients affected by metastatic colorectal cancer, those amenable to curative resection of CLM represent a preselected population with better tumor biology and longer survival. This hypothesis is supported by the fact that the only study reporting on rates of KRAS mutations after resection of CLM indicated a 25% rate of mutations in patients undergoing resection after receiving preoperative modern chemotherapy. 28 In this study, we analyzed the mutation status of multiple somatic genes and found that of 43 patients with at least 1 somatic gene mutation, the majority had a RAS mutation (n = 34), whereas only a small minority had mutations of PIK3CA (n = 5), BRAF (n = 2), CTTNB1 (n = 1), and AKT1 (n = 1). This finding confirms the dominance of RAS mutations in colorectal cancer and suggests that the less common mutations (of PIK3CA, BRAF, CTTNB1, and AKT1) are unlikely to contribute significantly to future overall outcome analyses of patients undergoing resection of CLM. However, it is still possible that, in future studies, these rare mutations could help to predict outcomes of specific subsets of patients with poor prognosis or specific metastatic patterns.
Only a few prior studies [16] [17] [18] have focused on mutation rates and recurrence patterns in patients with colorectal cancer. Tie et al 16 reported higher rates of RAS mutations in colorectal lung metastases than in CLM. In the current study, we specifically looked at patterns of recurrence after hepatectomy. The results indicate that, compared to wild-type RAS, RAS mutation is associated with a shorter 3-year lung RFS rate (34.6% vs 59.3%, P < 0.001), but not with a shorter liver RFS rate (43.8% vs 50.2%, P = 0.181) (Fig. 4) . These results suggest a propensity for RAS-mutated tumors to metastasize to lungs and are in line with the results of previous studies that have shown higher KRAS mutation rates in lung (62%) and brain (57%) metastases from colorectal cancer than in CLM (32%). 16, 17 This discordance in mutation rates suggests the possibility that KRASmutant tumors are biologically versatile and able to grow in different visceral organs and have higher capacity for systemic vascular (as opposed to portal vascular) tumor spread. These findings argue in favor of studying molecular heterogeneity and differences in biologic interaction between colon cancer tumor cells and host organ factors at different metastatic sites, in in vitro and in vivo models, comparing KRAS-mutant and KRAS-wild-type colorectal cancer.
In a previous study, indeterminate lung nodules were reported in 43% of patients undergoing chest CT before resection of CLM. Only 35% of indeterminate nodules proved to be lung metastases, and their presence was not associated with worse survival, leading the authors to conclude that the presence of indeterminate lung nodules should not preclude resection of CLM. 29 The findings from our current study, while supporting the role of preoperative chest CT before resection of CLM, suggest that nonspecific lung nodules in patients with RAS mutations may be more likely to represent metastatic disease. This information may help physicians select, among patients with multiple and bilobar CLM requiring extensive resection, those who may benefit from an aggressive surgical approach. In addition, our data favor the use of chest CT surveillance after resection of CLM in patients harboring a RAS mutation.
The RAS mutation rate in the current study (18%) is lower than the 47% RAS mutation rate reported in our previous study in patients undergoing resection of metachronous CLM. 15 We interpret the findings of our previous study as indicating that adjuvant chemotherapy for 6 months after resection of the primary tumor resulted in a selection pressure favoring the onset of metachronous liver metastases enriched for KRAS mutations and prevented metastases in a number of patients with primary tumors with wild-type KRAS-similar to the phenomenon by which antibiotic therapy can select for treatmentresistant bacteria. These interpretations are consistent with findings from other studies indicating that adjuvant FOLFOX for the primary tumor does not cause mutations in CLM. 30, 31 and that the mutation types remain concordant between the primary tumor and CLM in more than 90% of patients when the primary and the metastases are compared. [32] [33] [34] [35] [36] In contrast with our previous study, our current work focused on patients who underwent single-regimen preoperative modern chemotherapy for 2 to 3 months and excluded patients who had received multiple lines of chemotherapy. Therefore, the current study focused on a clinically preselected population of patients with favorable tumor biology accounting for the low mutation rate. In addition, the analysis of clinical and pathological differences between patients with mutant RAS and those with wild-type RAS indicated similar median numbers of chemotherapy cycles in the 2 groups (Table 1) . These data support the concept that preoperative chemotherapy for liver metastases does not affect the RAS mutation rate. 37 Taken together, these mutational data do not argue against the use of modern chemotherapy as adjuvant therapy for primary tumors or neoadjuvant therapy for liver metastases.
The limitations of this study include its retrospective nature and the selected patient population due to limited availability of specimens suitable for genetic analysis. However, the present analysis was based on a patient population with similar pathologic and clinical characteristics, and RAS mutation status well stratified patients with respect to prognosis and patterns of recurrence, even after exclusion of patients with very good pathologic response to chemotherapy (% of residual tumor cells < 5%), in whom genetic profiling was impossible due to very low proportion of residual viable tumor cells in the specimen and consequent insufficient DNA for genetic analysis.
CONCLUSIONS
RAS mutation status is a powerful predictor of OS, RFS, and lung recurrence after curative resection of CLM. These data indicate that the genetic profile of CLM can be used to improve selection of patients with CLM for surgery and predict outcome of patients with CLM. In addition, the finding of a higher rate of pathologic response in patients with wild-type RAS sets the stage for further studies focusing on somatic gene mutations and pattern of response associated with preoperative chemotherapy.
DISCUSSANTS
Dr. Bryan M. Clary (Durham, NC):
In the current era, questions regarding the treatment of colorectal metastases are not difficult to come by, although truly interesting questions are really a bit scarcer. Dr. Vauthey and his colleagues have demonstrated a proclivity toward identifying, I think, some of the more interesting aspects of this disease worthy of explanation.
It is important in understanding today's work to reflect on the backdrop of what was presented last year and published in the Annals of Surgery just this year from Nick and his group. In that study, which he referenced at the beginning of his talk, patients with recurrences after curative resection of primary colorectal cancer had poorer outcomes when oxaliplatin was part of their adjuvant chemotherapy regimens.
In extending this work, Dr. Vauthey, in today's presentation, provides, I think, a convincing argument that patients with RAS mutations have less favorable outcomes following partial hepatectomy for metastatic disease. It should be reemphasized, though, that only patients receiving prehepatectomy chemotherapy were included in today's talk, and specifically they had either irinotecan-or oxaliplatincontaining regimens. The results presented today are really not too surprising, as it has been duplicated in patients with unresectable metastatic disease who harbor RAS mutations.
The other interesting finding from today's work is that of the differential pattern of recurrence, specifically the heightened lung recurrences in patients with RAS mutations.
My principal questions to Dr. Vauthey really revolve around what to do with this information. In the manuscript associated with this presentation and in the summary slides, Dr. Vauthey and his coauthors suggest potentially using RAS status to be more selective in patients with high-risk tumor burdens potentially as a mechanism to help interpret indeterminate lung nodules and as a guide to the utilization of surveillance studies.
I'm a bit skeptical regarding this, as CT scans of the chest are already widespread in follow-up, and the long-term outcomes in their RAS-mutant patients actually was still quite respectable, with a five-year survival of over 45%.
So my questions are, number 1, does the administration of prehepatectomy chemotherapy have any influence on the rate of somatic mutations found in resected specimens? In your study published last year, which included patients with and without prehepatectomy chemotherapy, the mutation rate was 57%. In today's study, where every patient had prehepatectomy therapy, your mutation rate was only 22%. So, I would be interested to understand why that is, because I would have expected exactly the opposite.
The second question is, again, in light of your previous findings that adjuvant FOLFOX following curative primary tumor resections is associated with the development of more aggressive recurrences, should we consider changing our multimodality paradigm of treatment for hepatic colorectal metastases to just surgery alone for resectable patients, reserving chemotherapy only for those patients who subsequently recur?
This may seem a bit heretical, but there is no compelling data that adjuvant chemotherapy increases the cure rate following hepatectomy. And reserving the chemotherapy until the time of relapse would limit its use to only those patients who need it. And potentially, that chemotherapy would be a bit more effective at that time.
Reply from J.-N. Vauthey:
First, I will answer the question regarding the differences in KRAS mutation rates between our paper presented last year and our paper presented this year. In our paper from last year, we reported on the small subset of patients with metachronous colorectal liver metastases (CLM). The study showed worse disease-free and overall survival and a higher rate of KRAS mutations (47%) in patients who had received 6 months of postoperative FOLFOX for their primary colorectal cancer than in patients who had received 5-fluorouracil (KRAS mutation rate, 22%) or no chemotherapy (KRAS mutation rate, 20%). Our interpretation of this finding was that FOLFOX exerted a selection pressure favoring the survival of tumor cells with KRAS mutations, similar to the phenomenon by which antibiotic therapy can select treatment-resistant bacteria.
The current paper is our report on patients with CLM who underwent resection of CLM following a short course of preoperative oxaliplatin-or irinotecan-based chemotherapy. Could this preoperative chemotherapy have resulted in selection pressure favoring tumors with mutations? This appears unlikely given the overall low rate of RAS mutations, 18%, despite the use of preoperative chemotherapy in all patients. A previous report indicated a higher KRAS mutation rate (27%) in a surgical population of patients with CLM who had not received preoperative chemotherapy (Nash et al., Ann Surg Oncol, 2010;17:572-578). The favorable survival reported in the current study and the finding of a low RAS mutation rate do not argue against our current practice of limited preoperative chemotherapy (2-3 months before surgery) and postoperative chemotherapy (3-4 months after surgery) in patients with CLM.
How should our treatment of CLM be influenced by the data in our current paper? I believe that analysis of RAS mutation status in patients with CLM is a first step in a more personalized evaluation of the disease. RAS mutations are early events in the course of colorectal cancer and appear to be unaffected by preoperative chemotherapy for CLM. In addition, RAS appears to outperform the traditional clinicalpathological predictors of outcome. As such, RAS mutation status could be used to model prognosis before the use of chemotherapy or the traditional "test of time." We are now in a new era in which we proceed more aggressively with multiple liver resections and sequential surgeries. In this context, RAS mutation status may be useful early in treatment planning. In addition, RAS mutation status can be inferred on the basis of the mutation status of the primary tumor as there is evidence of greater than 90% mutation-status concordance between primary colorectal tumors and CLM.
DISCUSSANTS Dr. William O. Richards (Mobile, AL):
I want to get to the question about why RAS Mutational Status predicts recurrence and survival. Is it because the RAS mutation inhibits the effectiveness of the preoperative chemotherapy or is it the RAS mutation increases the metastatic potential of these tumors?
Reply from J.-N. Vauthey:
For this study, the data were derived from of a homogeneous population of patients who received 2 to 3 months of preoperative chemotherapy before resection of CLM. A previous paper predating the era of preoperative chemotherapy for CLM (Nash et al, Ann Surg Oncol, 2010;17:572-8) similarly indicated that KRAS drives the prognosis of patients with CLM. As such, we do not believe that there is an interaction between chemotherapy and RAS mutations; rather, we believe that prognosis is influenced by RAS mutation status irrespective of chemotherapy.
DISCUSSANTS Dr. Sean J. Mulvihill (Salt Lake City, UT):
